600664 哈药股份
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入12,256,4416.63%15,456,57813,808,76112,802,01610,788,457
减:营业总成本11,561,5154.70%14,807,71613,281,56512,386,05711,523,056
    其中:营业成本8,796,7902.43%11,404,77010,402,6939,766,0688,441,040
               财务费用25,95553.98%27,71567,61095,07450,511
               资产减值损失(12,046)-6.24%(45,067)(87,598)(54,225)(163,048)
公允价值变动收益0----------
投资收益12,786127.78%4,48340,32684935,382
    其中:对联营企业和合营企业的投资收益0----------
营业利润721,62550.34%659,629695,803642,413(942,108)
利润总额710,69348.91%650,540701,154630,534(968,648)
减:所得税费用162,94526.20%176,322188,942220,68976,602
净利润547,74857.33%474,218512,212409,846(1,045,250)
减:非控股权益39,462-31.56%78,95547,06238,76232,449
股东净利润508,28674.97%395,263465,150371,084(1,077,699)

市场价值指针
每股收益 (元) *0.20066.67%0.1600.1900.150-0.430
每股派息 (元) *------------
每股净资产 (元) *2.06912.81%1.8741.7151.5281.388
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容